ifosfamide has been researched along with Methemoglobinemia in 2 studies
Methemoglobinemia: The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 7.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
| " At present, MB is the first line of treatment in methemoglobinemias, is used frequently in the treatment of ifosfamide-induced encephalopathy, and is routinely employed as a diagnostic tool in surgical procedures." | 4.87 | Cellular and molecular actions of Methylene Blue in the nervous system. ( Hasan, M; Lorke, DE; Oz, M; Petroianu, GA, 2011) |
| " In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 3.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oz, M | 1 |
| Lorke, DE | 1 |
| Hasan, M | 1 |
| Petroianu, GA | 1 |
| Hadjiliadis, D | 1 |
| Govert, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic[NCT04619290] | Phase 1 | 46 participants (Anticipated) | Interventional | 2020-10-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Methemoglobinemia
| Article | Year |
|---|---|
Cellular and molecular actions of Methylene Blue in the nervous system.
Topics: Alzheimer Disease; Animals; Humans; Ifosfamide; Methemoglobinemia; Methylene Blue; Neurons | 2011 |
1 other study available for ifosfamide and Methemoglobinemia
| Article | Year |
|---|---|
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Diagnosis, Differential; Female; Humans; Ifosfamide; | 2000 |